Bright Future Pharmaceutical Laboratories Ltd (09939.HK): The GT20029 gel has reached the primary endpoint in the Phase II clinical trial for the treatment of acne in China.

Zhitong Finance and Economics APP news, Kangtuo Pharmaceutical-B (09939.HK) announced that the company's independently developed novel targeted androgen receptor (AR) protein degrading chimeric compound (PROTAC) GT20029 for the treatment of acne has read out top-line data from its Phase II clinical trial. The data shows that the Phase II clinical trial has successfully met its primary endpoint, with results that are statistically significant and clinically meaningful. The compound has demonstrated excellent efficacy, safety, and pharmacokinetic characteristics, and the recommended dose for Phase III clinical trial has been determined to be 0.5%. Detailed top-line results are expected to be published in academic journals or presented at academic conferences in the future.